DOPAMET TAB 500MG 500 MG — DIN 00353639
METHYLDOPA : 500 MG · ICN CANADA LTD. · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is DOPAMET TAB 500MG?
DOPAMET TAB 500MG 500 MG contains METHYLDOPA : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 00353639, held by ICN CANADA LTD., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 26-Apr-2005. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Methyldopa (Racemic) cost around the world?
Methyldopa (Racemic) is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 5 | 7 | SAR███.██ |
| Morocco | PPV (public price) | 2 | 3 | MAD███.██ |
| Australia | ex-manufacturer | 2 | 2 | AUD███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
19 pack listings across 15 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Methyldopa (Racemic) pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Methyldopa (Racemic) in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Methyldopa (Racemic), across 20 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AA PHARMA INC | 3 | 3 | METHYLDOPA | Sourceable in Canada |
| MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | 4 | 0 | ALDOMET ESTER HCL INJ, ALDOMET TAB 125MG, ALDOMET TAB 250MG, ALDOMET TAB 500MG | No marketed DIN |
| ICN CANADA LTD. | 3 | 0 | DOPAMET TAB 125MG, DOPAMET TAB 250MG, DOPAMET TAB 500MG | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVO-MEDOPA TAB 125MG, NOVO-MEDOPA TAB 250MG, NOVO-MEDOPA TAB 500MG | No marketed DIN |
| NU-PHARM INC | 3 | 0 | NU-MEDOPA TAB 125MG, NU-MEDOPA TAB 250MG, NU-MEDOPA TAB 500MG | No marketed DIN |
| PRO DOC LIMITEE | 3 | 0 | METHYLDOPA 125 TAB 125MG, METHYLDOPA 250 TAB, METHYLDOPA 500 TAB 500MG | No marketed DIN |
| MEDIC LABORATORY LTÉE | 1 | 0 | MEDIMET 250TAB | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Methyldopa (Racemic) |
|---|---|
| ATC code | C02AB02 |
| AHFS class | 28:16.04.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00353639 |
|---|---|
| DIN (unpadded, as printed on some documents) | 353639 |
| Brand name | DOPAMET TAB 500MG |
| Generic / active ingredient | METHYLDOPA : 500 MG |
| Market authorization holder | ICN CANADA LTD. |
| Health Canada schedule | Prescription |
| ATC code | C02AB02 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C02AB |
| Current status | CANCELLED POST MARKET |
| Status date | 26-Apr-2005 |
| Original market date | 1976-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 20 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| METHYLDOPA | 125 MG | TABLET | AA PHARMA INC | MARKETED | 00360252 |
| METHYLDOPA | 500 MG | TABLET | AA PHARMA INC | MARKETED | 00426830 |
| METHYLDOPA | 250 MG | TABLET | AA PHARMA INC | MARKETED | 00360260 |
| ALDOMET ESTER HCL INJ | 250 MG / 5 ML | LIQUID | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 00016187 |
| ALDOMET TAB 125MG | 125 MG | TABLET | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 00016551 |
| ALDOMET TAB 250MG | 250 MG | TABLET | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 00016578 |
| ALDOMET TAB 500MG | 500 MG | TABLET | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 00016586 |
| DOPAMET TAB 125MG | 125 MG | TABLET | ICN CANADA LTD. | CANCELLED POST MARKET | 00353620 |
| DOPAMET TAB 250MG | 250 MG | TABLET | ICN CANADA LTD. | CANCELLED POST MARKET | 00250392 |
| MEDIMET 250TAB | 250 MG | TABLET | MEDIC LABORATORY LTÉE | CANCELLED POST MARKET | 00385077 |
2 · Same class — other molecules in ATC C02AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Methyldopa (Racemic) | ALDOMET ESTER HCL INJ · ALDOMET TAB 125MG · ALDOMET TAB 250MG · ALDOMET TAB 500MG · +14 more | 20 | 3 | Yes |
| Methyldopa (Levorotatory) | METHYLDOPA TABLETS 125MG · METHYLDOPA TABLETS 250MG · METHYLDOPA TABLETS 500MG | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C02AC | Clonidine · Guanfacine | 50 | 33 |
| C02AA | Reserpine | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DOPAMET TAB 500MG called?
The same molecule, Methyldopa (Racemic), is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Aldomet | Latin | Australia, Bahrain, Morocco, Saudi Arabia |
| Presinol | Latin | Iceland |
| ALDOPA | Latin | Morocco |
| Hydopa | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.